Abstract P3-11-05: Predictive gene signatures of adjuvant capecitabine benefit in triple negative breast cancer in the FinXX trial

Saranya Chumsri(Jacksonville College), E. Aubrey Thompson(Mayo Clinic in Florida), Afshin Mashadi-Hossein(University of Helsinki), LS Lauttia(University of Helsinki), Henrik Lindman(Uppsala University), Karama Asleh(University of British Columbia), TO Nielsen(University of Helsinki), Heikki Joensuu(Orion Corporation (Finland)), HA Brauer(University of Helsinki)
Cancer Research
February 15, 2019
10.1158/1538-7445.sabcs18-p3-11-05
Cited by 1

Related Papers

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|Annals of Oncology|2014|1.3k